BACKGROUND Group B streptococcus is the leading reason behind infection in babies. providing at among the chosen private hospitals and who offered consent through the research period. There were no exclusion criteria. INTERVENTIONS No interventions were performed. MAIN OUTCOME MEASURES (1) To test the feasibility of collecting serum at delivery from a large cohort of pregnant women. (2) To test the key operational aspects for a proposed large serocorrelates study. (3) To test the feasibility of collecting samples from those with invasive group B streptococcus. RESULTS A total of 1823 women were recruited during the study period. Overall, 85% of serum samples were collected at three sites collecting only cord blood. Tenofovir (Viread) At the two sites collecting maternal, cord and infant blood samples, the collection Tenofovir (Viread) rate was 60%. A total of 614 Rabbit Polyclonal to PTGDR women were screened for group B streptococcus with a colonisation rate of 22% (serotype distribution: 30% III, 25% Ia, 16% II, 14% Ib, 14% V and 1% IV). A blood sample was collected from 34 infants who were born to colonised women. Maternal and infant blood and the bacterial isolates for 15 newborns who developed invasive group B streptococcal disease during the study period were collected (serotype distribution: 29% Tenofovir (Viread) III, 29% II, 21% Ia, 7% Ib, 7% IV and 7% V). LIMITATIONS Recruitment and sample collection were dependent on the presence of research midwives rather than the whole clinical team. Furthermore, individualised consent limited the real amount of ladies who could possibly be contacted every day, and site set-up for the Tenofovir (Viread) nationwide surveillance research as well as the limited time frame of the feasibility research limited recruitment of most eligible participants. CONCLUSIONS We’ve confirmed the feasibility of collecting and digesting rectovaginal bloodstream and swabs examples in women that are pregnant, aswell as examples from people that have intrusive group B streptococcal Tenofovir (Viread) disease. We’ve made tips for the recruitment of instances within the suggested GBS3 research as well as for settings both within GBS3 so that as an expansion of the feasibility research. FUTURE WORK A big case-control research comparing particular immunoglobulin G amounts in moms whose babies develop intrusive group B streptococcal disease with those in colonised moms whose infants usually do not develop intrusive group B streptococcal disease is preferred. TRIAL Sign up Current Controlled Tests ISRCTN49326091; IRAS task identification quantity 246149/REC reference quantity 18/WM/0147. Financing This task was funded from the Country wide Institute for Wellness Research (NIHR) Wellness Technology Assessment program and you will be released completely in Wellness Technology Evaluation; Vol. 23, No. 67. Start to see the NIHR Publications Library website for even more project information. Total text of the article are available in Bookshelf..